Please login to the form below

Not currently logged in
Email:
Password:

Mekinist

This page shows the latest Mekinist news and features for those working in and with pharma, biotech and healthcare.

Half of European cancer drug trials ‘biased’, says BMJ

Half of European cancer drug trials ‘biased’, says BMJ

That included Servier’s leukaemia treatment Oncaspar(pegaspargase), which had five studies deemed to be at risk, while others included Novartis’  Mekinist(trametinib; three studies) and Pfizer’s  Ibrance(palbociclib; two

Latest news

  • Novartis wins key adjuvant Taf/Mek approval in Europe Novartis wins key adjuvant Taf/Mek approval in Europe

    Ex-GSK duo on course for first blockbuster year. Novartis’ cancer combination Tafinlar and Mekinist has been approved by the EMA for adjuvant treatment of advanced melanoma in order to prevent ... The EMA has approved Tafinlar (dabrafenib) and Mekinist

  • Novartis scores but Roche misses in melanoma trials Novartis scores but Roche misses in melanoma trials

    Phase III trial combo success for Tafinlar/Mekinist “unprecedented”. A phase III trial of Novartis Tafinlar and Mekinist has confirmed the potential of the pair in the post-surgical treatment of ... The combination of Novartis BRAF inhibitor Tafinlar

  • Novartis gets lung cancer OK for Tafinlar/Mekinist combo Novartis gets lung cancer OK for Tafinlar/Mekinist combo

    The FDA has granted priority review to Tafinlar/Mekinist for the treatment of BRAF mutant NSCLC with disease progression on or after platinum-containing chemotherapy. ... Novartis acquired Tafinlar and Mekinist as part of its asset-swap deal with

  • J&J gets CHMP backing for broader Darzalex use J&J gets CHMP backing for broader Darzalex use

    CHMP round-up. At its meeting last week the CHMP also gave its blessing to the combination of Novartis' Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF-positive non-small cell lung

  • The UK's new Cancer Drugs Fund The UK's new Cancer Drugs Fund

    Gaining the greenlight were Novartis' Zykadia (ceritinib) for lung cancer and melanoma combination Tafinlar (dabrafenib) and Mekinist (trametinib), and Servier's Lonsurf (trifluridine/tipiracil HCl) for bowel cancer.

More from news
Approximately 12 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    GSK's recently approved MEK inhibitor Mekinist and BRAF inhibitor Tafinlar will position Novartis to become a leader in the potential blockbuster market for metastatic melanoma, neglected by their current portfolio.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...

Infographics